Security Snapshot

Xenon Pharmaceuticals Inc. - Common Stock (XENE) Institutional Ownership

CUSIP: 98420N105

13F Institutional Holders and Ownership History from Q4 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

245

Shares (Excl. Options)

84,413,479

Price

$44.82

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock
Symbol
XENE on Nasdaq
Shares outstanding
76,851,274
Price per share
$56.85
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
84,413,479
Total reported value
$3,783,396,815
% of total 13F portfolios
0%
Share change
-594,096
Value change
-$19,907,308
Number of holders
245
Price from insider filings
$56.85
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • XENE - Xenon Pharmaceuticals Inc. - Common Stock is tracked under CUSIP 98420N105.
  • 245 institutions reported positions in Q4 2025.
  • 4 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 245 to 92 between Q4 2025 and Q1 2026.
  • Reported value moved from $3,783,396,815 to $433,882,964.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 245 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 98420N105?
CUSIP 98420N105 identifies XENE - Xenon Pharmaceuticals Inc. - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Xenon Pharmaceuticals Inc. - Common Stock (XENE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 12% +12% $277,261,485 +$30,579,986 8,824,363 +12% FMR LLC 30 Jun 2025
WELLINGTON MANAGEMENT GROUP LLP 6.2% +113% $213,557,395 +$116,084,607 4,764,779 +119% Wellington Management Group LLP 31 Dec 2025
BlackRock, Inc. 6.2% $148,914,864 4,757,709 BlackRock, Inc. 30 Jun 2025
JANUS HENDERSON GROUP PLC 5.1% $158,346,983 3,943,885 JANUS HENDERSON GROUP PLC 30 Sep 2025

As of 31 Dec 2025, 245 institutional investors reported holding 84,413,479 shares of Xenon Pharmaceuticals Inc. - Common Stock (XENE). This represents 110% of the company’s total 76,851,274 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) together control 77% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 12% 8,920,250 +0.02% 0.02% $399,805,605
Avoro Capital Advisors LLC 7.1% 5,424,444 +0.45% 2.4% $243,123,580
BlackRock, Inc. 6.6% 5,100,284 +6.9% 0% $228,594,728
WELLINGTON MANAGEMENT GROUP LLP 6.2% 4,764,779 +32% 0.04% $213,557,396
Driehaus Capital Management LLC 5.9% 4,538,691 +8.9% 1.4% $203,424,131
JANUS HENDERSON GROUP PLC 5.3% 4,084,034 +3.6% 0.08% $183,109,819
Capital International Investors 4.4% 3,414,959 +7.3% 0.02% $153,058,462
Polar Capital Holdings Plc 3.2% 2,465,694 -3.2% 0.51% $110,512,405
BRAIDWELL LP 2.4% 1,825,076 -49% 2.6% $81,799,906
Commodore Capital LP 2.3% 1,800,000 -33% 5.4% $80,676,000
ALLIANCEBERNSTEIN L.P. 2.1% 1,593,814 -3.7% 0.02% $71,434,743
JPMORGAN CHASE & CO 1.9% 1,494,032 +6.8% 0% $66,962,514
STATE STREET CORP 1.9% 1,492,550 +1.8% 0% $66,896,091
CITADEL ADVISORS LLC 1.7% 1,321,213 +38% 0.04% $59,216,767
JENNISON ASSOCIATES LLC 1.7% 1,292,055 +14% 0.03% $57,909,905
Holocene Advisors, LP 1.7% 1,282,081 -35% 0.12% $57,462,870
Affinity Asset Advisors, LLC 1.6% 1,250,000 -11% 4% $56,025,000
WESTFIELD CAPITAL MANAGEMENT CO LP 1.6% 1,226,771 +1.7% 0.23% $54,983,876
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 1.4% 1,060,221 +58% 0.05% $47,519,000
GEODE CAPITAL MANAGEMENT, LLC 1.2% 952,679 -2.5% 0% $42,692,208
PRICE T ROWE ASSOCIATES INC /MD/ 1.1% 862,300 +1969% 0% $38,650,000
Siren, L.L.C. 1.1% 812,761 0% 1.1% $36,427,948
First Turn Management, LLC 1% 799,743 0% 4.1% $35,844,481
Rock Springs Capital Management LP 1% 787,788 -7.5% 1.8% $35,308,658
FRANKLIN RESOURCES INC 0.99% 758,059 +8.9% 0.01% $33,976,204

Institutional Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 7,474,597 $433,882,964 +$13,670,342 $58.15 92
2025 Q4 84,413,479 $3,783,396,815 -$19,907,308 $44.82 245
2025 Q3 84,320,819 $3,385,181,214 +$50,763,750 $40.15 218
2025 Q2 83,131,091 $2,602,180,922 +$191,395,540 $31.30 206
2025 Q1 76,712,560 $2,576,157,111 +$10,187,791 $33.55 206
2024 Q4 76,301,942 $2,990,887,419 +$29,910,038 $39.20 209
2024 Q3 74,889,394 $2,949,541,361 +$275,979 $39.37 202
2024 Q2 74,169,549 $2,891,734,051 +$25,968,930 $38.99 212
2024 Q1 73,488,096 $3,163,931,600 +$66,663,770 $43.05 220
2023 Q4 72,058,517 $3,319,081,625 +$473,994,183 $46.06 204
2023 Q3 61,366,625 $2,096,353,515 +$8,680,142 $34.16 180
2023 Q2 61,306,738 $2,360,645,061 +$10,880,022 $38.50 173
2023 Q1 61,134,066 $2,185,894,799 +$24,625,634 $35.79 161
2022 Q4 60,466,775 $2,384,173,156 +$38,699,727 $39.43 157
2022 Q3 57,955,532 $2,092,174,527 +$39,481,459 $36.10 151
2022 Q2 57,007,759 $1,734,195,451 +$237,069,658 $30.42 149
2022 Q1 49,043,946 $1,499,284,580 +$44,953,028 $30.57 128
2021 Q4 47,689,350 $1,489,826,062 +$453,547,589 $31.24 129
2021 Q3 34,071,867 $521,082,671 +$347,889 $15.28 113
2021 Q2 33,296,183 $619,964,580 +$2,566,015 $18.62 99
2021 Q1 32,964,044 $590,006,963 +$88,828,095 $17.90 88
2020 Q4 28,020,659 $430,912,842 -$1,905,185 $15.38 79
2020 Q3 27,927,587 $309,203,900 -$546,988 $11.07 79
2020 Q2 27,956,934 $350,580,052 +$8,434,389 $12.54 78
2020 Q1 27,692,215 $313,869,842 +$101,491,596 $11.34 69
2019 Q4 18,704,750 $245,218,634 +$22,437,621 $13.11 66
2019 Q3 16,095,522 $145,000,637 -$14,668,511 $9.01 53
2019 Q2 17,563,087 $173,174,992 -$1,947,261 $9.86 59
2019 Q1 17,736,748 $180,206,294 +$3,000,347 $10.16 61
2018 Q4 17,450,658 $110,112,206 -$24,376,594 $6.31 56
2018 Q3 17,678,662 $234,229,778 +$115,388,474 $13.20 59
2018 Q2 9,038,748 $83,159,306 +$29,134,581 $9.20 41
2018 Q1 6,350,539 $31,098,772 -$13,812,327 $4.90 35
2017 Q4 9,156,573 $25,870,113 -$498,226 $2.83 31
2017 Q3 9,321,729 $27,499,118 -$1,981,003 $2.95 31
2017 Q2 9,948,182 $31,335,126 -$1,135,510 $3.15 39
2017 Q1 10,076,433 $40,304,200 -$3,171,773 $4.00 37
2016 Q4 10,492,956 $80,798,000 +$1,871,735 $7.70 31
2016 Q3 9,943,719 $80,586,000 +$37,001,698 $8.10 31
2016 Q2 5,377,516 $32,048,000 -$2,510,463 $5.90 21
2016 Q1 5,708,042 $39,935,000 -$1,434,240 $6.99 25
2015 Q4 5,776,167 $46,491,000 +$2,273,755 $8.04 25
2015 Q3 5,476,932 $45,239,000 +$5,117,394 $8.26 25
2015 Q2 4,806,596 $55,420,000 +$3,173,766 $11.53 25
2015 Q1 4,449,844 $75,166,316 +$2,920,417 $16.86 23
2014 Q4 4,275,072 $83,141,000 +$76,655,000 $19.75 16
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .